Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (101-110 of 146) with videos related to

Pageof 15
Sort By:
Medical Oncology (Northwood, London, England)|June 30, 2025
Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001)Hidekazu Suzuki, Akito Hata, Takaaki Tokito, et al.
Frontiers in Neuroscience|January 1, 2021
Anti-sortilin1 Antibody Up-Regulates Progranulin <i>via</i> Sortilin1 Down-RegulationShuuichi Miyakawa, Hiroyuki Sakuma, Dnyaneshwar Warude, et al.
Anticancer Research|July 1, 2015
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)Tomoyuki Otsuka, Masahide Mori, Yukihiro Yano, et al.
International Journal of Hematology|January 26, 2022
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trialYoshinori Imamura, Kazunori Otsui, Kenta Mori, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2015
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Journal of Medicinal Chemistry|August 4, 2021
Design, Synthesis, and Evaluation of <sup>11</sup>C-Labeled 3-Acetyl-Indole Derivatives as a Novel Positron Emission Tomography Imaging Agent for Diacylglycerol Kinase Gamma (DGKγ) in BrainYasushi Hattori, Tomoteru Yamasaki, Tomohiro Ohashi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2021
Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective studyYoko Tsukita, Takaya Yamamoto, Hiroshi Mayahara, et al.
Molecular and Clinical Oncology|April 29, 2014
Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patientsJumpei Takeshita, Katsuhiro Masago, Shiro Fujita, et al.
JTO Clinical and Research Reports|October 12, 2023
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)Motoko Tachihara, Akito Hata, Takaaki Tokito, et al.
Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
Medical Oncology (Northwood, London, England)|June 30, 2025
Phase II study of carboplatin + weekly paclitaxel for advanced lung squamous cell carcinoma with idiopathic interstitial pneumonia (Hanshin Cancer Group IP001)Hidekazu Suzuki, Akito Hata, Takaaki Tokito, et al.
Frontiers in Neuroscience|January 1, 2021
Anti-sortilin1 Antibody Up-Regulates Progranulin <i>via</i> Sortilin1 Down-RegulationShuuichi Miyakawa, Hiroyuki Sakuma, Dnyaneshwar Warude, et al.
Anticancer Research|July 1, 2015
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)Tomoyuki Otsuka, Masahide Mori, Yukihiro Yano, et al.
International Journal of Hematology|January 26, 2022
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trialYoshinori Imamura, Kazunori Otsui, Kenta Mori, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2015
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.
Journal of Medicinal Chemistry|August 4, 2021
Design, Synthesis, and Evaluation of <sup>11</sup>C-Labeled 3-Acetyl-Indole Derivatives as a Novel Positron Emission Tomography Imaging Agent for Diacylglycerol Kinase Gamma (DGKγ) in BrainYasushi Hattori, Tomoteru Yamasaki, Tomohiro Ohashi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2021
Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective studyYoko Tsukita, Takaya Yamamoto, Hiroshi Mayahara, et al.
Molecular and Clinical Oncology|April 29, 2014
Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patientsJumpei Takeshita, Katsuhiro Masago, Shiro Fujita, et al.
JTO Clinical and Research Reports|October 12, 2023
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)Motoko Tachihara, Akito Hata, Takaaki Tokito, et al.
Pageof 15